HOME >> MEDICINE >> NEWS
ACTOplus met (pioglitazone HCl and metformin HCl)

LINCOLNSHIRE, Ill., November 1, 2005 Takeda Pharmaceuticals North America, Inc. today announced that ACTOplus metTM (pioglitazone HCl and metformin HCl) is now available by prescription in pharmacies across the United States for the treatment of type 2 diabetes. This is the second Takeda product launch in the United States this year, following the approval of ROZEREMTM (ramelteon) on July 22, 2005.

ACTOplus met combines ACTOS® (pioglitazone HCl) and metformin, two widely used diabetes medications, in a single tablet. ACTOS directly targets insulin resistance, a condition where the body does not efficiently use the insulin it produces, and metformin acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels.

"Takeda is pleased to provide ACTOplus met, an important addition to the ACTOS family of products," said Mark Booth, president of Takeda. "Since most people with type 2 diabetes take multiple therapies to reach their target glucose levels, we believe that this combination pill will offer an effective, convenient new treatment option for patients."

To offer physicians greater flexibility in treating their patients' needs, ACTOplus met will be available in two dosages of pioglitazone/metformin 15 mg/500 mg and 15 mg/850 mg both of which are to be given once a day or in divided doses not exceeding the maximum recommended daily doses of pioglitazone 45 mg and metformin 2,550 mg, according to the approved labeling.

According to the American Diabetes Association, diabetes affects more than 18 million people, and type 2 diabetes is the most common form of the disease. Both ACTOS and metformin are widely used medications in the treatment of type 2 diabetes and both have a known safety profile. Combining these medications may provide patients with an easier way to take th
'"/>

Contact: Amy Losak
amy.losak@ketchum.com
646-935-3917
Ketchum
1-Nov-2005


Page: 1 2 3

Related medicine news :

1. Takeda submits new drug application for extended-release type 2 diabetes medication, ACTOplus met
2. ACTOS (pioglitazone HCl) demonstrates significant improvements in cardiovascular outcomes
3. ACTOS (pioglitazone HCl) to be studied in new trial
4. ACTOS (pioglitazone HCl) significantly improved components of diabetic dyslipidemia
5. PRESERVE- 2-year study of initial combo therapy with nateglinide or glyburide + metformin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... ... September 01, 2020 , ... Feeding Matters , the ... with Pediatric Feeding Disorder (PFD), is pleased to announce that the U.S. Centers for ... code (R code) in the next edition of the U.S. International Classification of ...
(Date:8/31/2020)... ... ... dear friend has cancer? , It’s hard to hear your doctor say the words “You ... shock wears off, the questions and fears can be overwhelming. , How should I respond? ... are failing me. I’m scared. I want to DO something. , We’ve talked to experts ...
(Date:8/31/2020)... ... 2020 , ... Smile Brands Inc., one of the nation’s ... today announced the grand opening of another affiliated Bright Now! Dental office ... hours, a comfortable office, and full-service care at the new Beaumont location. The ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... intended to improve outcomes for patients with advanced heart failure, today announced that ... grant in the amount of $555,358 from the National Heart, Lung, and Blood ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... set out to continue helping the specialty-diet community connect with great, gluten-free ... products, get coupons, enter giveaways, chat with brands & watch over 50 educational ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... , ... September 01, 2020 , ... ... technologies, will host the Agilent Science and Technology Virtual Symposium 2020 (ASTVS ... symposium, Agilent will open a suite of Live webinars and Networking sessions, with ...
(Date:9/1/2020)... ... September 01, 2020 , ... Neil Oberfeld of ... Secretary to the Board of Trustees and committee chair of the Governance Committee ... a Denver-based nonprofit organization that fights for the education, health, and financial stability ...
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers ... Control (CDC), About 3% of breast cancers (about 7,500 women per year) and 10% ... BRCA1 and BRCA2 genes. Both genes are detectable in the Women’s Excellence Genetic ...
Breaking Medicine Technology:
Cached News: